Latest Commercialisation News

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Provaris Energy has launched a capital-lite revenue model designed to generate early cash flow with minimal capital expenditure, alongside securing a major hydrogen supply agreement with Uniper Global Commodities. The company targets first hydrogen deliveries by early 2029, advancing its position in Europe's hydrogen supply chain.

Environmental Clean Technologies Limited (ECT) has raised $750,000 through a two-tranche placement to fund its innovative COLDry Fertiliser Project and pursue strategic acquisitions, alongside key board changes.

Li-S Energy reports a $2.67 million net loss for H1 FY25 but marks significant milestones in lithium sulfur battery production and strategic partnerships.

Lincoln Minerals is accelerating development across its diversified portfolio of critical minerals projects in South Australia's Gawler Craton, targeting copper, uranium, graphite, and high-purity iron to meet global electrification and decarbonization demands.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Bass Oil Limited reported a 2.9% increase in total sales revenue for January 2025, driven by steady daily production and notable gains in both the Cooper Basin and Indonesian operations. The company is advancing gas appraisal efforts that could unlock significant new resources.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Green Critical Minerals has announced a major breakthrough with its VHD Graphite technology, delivering thermal diffusivity far surpassing copper and aluminium, promising a revolution in AI and high-performance electronics cooling.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Cyclone Metals has secured a pivotal development agreement with Vale, unlocking up to USD 138 million in funding for the Iron Bear iron ore project in Canada and setting a clear path to production.

Macarthur Minerals Limited reported a substantial loss of A$25.6 million for the nine months ending December 31, 2024, driven largely by the sale of its Hematite Project. Despite this setback, the company outlines plans for future funding and operational adjustments to sustain its business.